T1	Multiplier 33 41	3 cycles
T2	Drug 47 57	bortezomib
T3	Procedure 64 81	induction regimen
R1	AND Arg1:T3 Arg2:T2	
R2	Has_multiplier Arg1:T3 Arg2:T1	
T4	Qualifier 105 120	NCCN guidelines
R3	Has_qualifier Arg1:T3 Arg2:T4	
T5	Value 131 165	no evidence of disease progression
T6	Measurement 180 193	IMWG criteria
R4	Has_value Arg1:T6 Arg2:T5	
T7	Measurement 295 325	criteria for a diagnosis of MM
T8	Value 287 290	all
R5	Has_value Arg1:T7 Arg2:T8	
T9	Condition 214 252	light chain and free light chain (FLC)
A1	Optional T9
R6	AND Arg1:T9 Arg2:T7	
T10	Mood 379 390	eligible to
T11	Procedure 405 416	IRD regimen
R7	Has_mood Arg1:T11 Arg2:T10	
T12	Measurement 419 479	Eastern Cooperative Oncology Group (ECOG) performance status
T13	Value 512 522	0, 1, or 2
R8	Has_value Arg1:T12 Arg2:T13	
T14	Temporal 523 544	at time of enrollment
R9	Has_temporal Arg1:T12 Arg2:T14	
